Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda,MD 20892, USA.
J Infect Dis. 2013 Aug 1;208(3):418-22. doi: 10.1093/infdis/jit180. Epub 2013 Apr 30.
H5 DNA priming was previously shown to improve the antibody response to influenza A(H5N1) monovalent inactivated vaccine (MIV) among individuals for whom there was a 24-week interval between prime and boost receipt. This study defines the shortest prime-boost interval associated with an improved response to MIV.
We administered H5 DNA followed by MIV at intervals of 4, 8, 12, 16, or 24 weeks and compared responses to that of 2 doses of MIV (prime-boost interval, 24 weeks).
H5 DNA priming with an MIV boost ≥12 weeks later showed an improved response, with a positive hemagglutination inhibition (HAI) titer in 91% of recipients (geometric mean titer [GMT], 141-206), compared with 55%-70% of recipients with an H5 DNA and MIV prime-boost interval of ≤8 weeks (GMT, 51-70) and 44% with an MIV-MIV prime-boost interval of 24 weeks (GMT, 27).
H5 DNA priming enhances antibody responses after an MIV boost when the prime-boost interval is 12-24 weeks. Clinical Trials Registration. NCT01086657.
先前的研究表明，在首剂和加强针之间间隔 24 周的情况下，H5 DNA 引发可提高对甲型 H5N1 单价灭活疫苗（MIV）的抗体反应。本研究旨在确定与 MIV 反应改善相关的最短的首剂和加强针间隔。
我们在 4、8、12、16 或 24 周的间隔时间内给予 H5 DNA 后再给予 MIV，并将其与 2 剂 MIV（首剂和加强针间隔 24 周）的反应进行比较。
H5 DNA 引发后至少 12 周加强 MIV 接种显示出改善的反应，91%的接种者出现阳性血凝抑制（HAI）滴度（几何平均滴度[GMT]，141-206），而 H5 DNA 和 MIV 首剂和加强针间隔≤8 周的接种者为 55%-70%（GMT，51-70），而 MIV-MIV 首剂和加强针间隔 24 周的接种者为 44%（GMT，27）。
H5 DNA 引发可增强 MIV 加强针后的抗体反应，首剂和加强针间隔为 12-24 周。临床试验注册。NCT01086657。
